Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(1-((2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl)-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno(2,3-d)pyrimidin-3-yl)-2-methylpropanoic Acid
2. Gs-0976
1. Nd-630
2. 1434635-54-7
3. Gs-acc
4. Ndi-010976
5. Gs-0976
6. Firsocostat [usan]
7. Xe10njq95m
8. 2-[1-[(2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl]-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno[2,3-d]pyrimidin-3-yl]-2-methylpropanoic Acid
9. (r)-2-(1-(2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-5-methyl-6-(oxazol-2-yl)-2,4-dioxo-1,4-dihydrothieno[2,3-d]pyrimidin-3(2h)-yl)-2-methylpropanoic Acid
10. 2-(1-((2r)-2-(2-methoxyphenyl)-2-(oxan-4-yloxy)ethyl)-5-methyl-6-(1,3-oxazol-2-yl)-2,4-dioxothieno(2,3-d)pyrimidin-3-yl)-2-methylpropanoic Acid
11. Firsocostat [inn]
12. Firsocostat (usan/inn)
13. Unii-xe10njq95m
14. Firsocostat (gs-0976)
15. Firsocostat [who-dd]
16. Schembl14945041
17. Gtpl10645
18. Amy16826
19. Ex-a2586
20. Firsocostat(nd-630,gs-0976)
21. Nd 630;nd630
22. S8893
23. Who 10738
24. Akos037648731
25. Zinc207531097
26. Cs-6509
27. Ac-31460
28. Bs-15388
29. Hy-16901
30. Nd-630; Ndi-010976; Firsocostat
31. D11640
32. 1,4-dihydro-1-((2r)-2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-.alpha.,.alpha.,5-trimethyl-6-(2-oxazolyl)-2,4-dioxothieno(2,3-d)pyrimidine-3(2h)-acetic Acid
33. 1,4-dihydro-1-((2r)-2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-alpha,alpha,5-trimethyl-6-(2-oxazolyl)-2,4-dioxothieno(2,3-d)pyrimidine-3(2h)-acetic Acid
34. 2-[1-[(r)-beta-[(tetrahydro-2h-pyran-4-yl)oxy]-2-methoxyphenethyl]-2,4-dioxo-5-methyl-6-(oxazole-2-yl)-1,2-dihydrothieno[2,3-d]pyrimidine-3(4h)-yl]-2-methylpropanoic Acid
35. Thieno(2,3-d)pyrimidine-3(2h)-acetic Acid, 1,4-dihydro-1-((2r)-2-(2-methoxyphenyl)-2-((tetrahydro-2h-pyran-4-yl)oxy)ethyl)-.alpha.,.alpha.,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-
| Molecular Weight | 569.6 g/mol |
|---|---|
| Molecular Formula | C28H31N3O8S |
| XLogP3 | 3.2 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 9 |
| Exact Mass | 569.18318613 g/mol |
| Monoisotopic Mass | 569.18318613 g/mol |
| Topological Polar Surface Area | 160 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 947 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Drugs in Development
Details:
The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-alcoholic steatohepatitis.
Lead Product(s): Semaglutide,Cilofexor,Firsocostat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Rybelsus
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Novo Nordisk
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2020
Lead Product(s) : Semaglutide,Cilofexor,Firsocostat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Novo Nordisk
Deal Size : Not Applicable
Deal Type : Not Applicable
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
Details : The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor firsocostat over 24 weeks in 108 people with non-al...
Brand Name : Rybelsus
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 15, 2020
Details:
Real-world data from several studies presented at ILC demonstrate that Epclusa® (400 mg sofosbuvir/100 mg velpatasvir) is effective in curing hepatitis C (HCV) in a broad range of people and can be utilized in underserved populations.
Lead Product(s): Cilofexor,Firsocostat
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: GS-9674
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
Lead Product(s) : Cilofexor,Firsocostat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Real-world data from several studies presented at ILC demonstrate that Epclusa® (400 mg sofosbuvir/100 mg velpatasvir) is effective in curing hepatitis C (HCV) in a broad range of people and can be utilized in underserved populations.
Brand Name : GS-9674
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Firsocostat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Firsocostat, including repackagers and relabelers. The FDA regulates Firsocostat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Firsocostat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Firsocostat supplier is an individual or a company that provides Firsocostat active pharmaceutical ingredient (API) or Firsocostat finished formulations upon request. The Firsocostat suppliers may include Firsocostat API manufacturers, exporters, distributors and traders.
Firsocostat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Firsocostat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Firsocostat GMP manufacturer or Firsocostat GMP API supplier for your needs.
A Firsocostat CoA (Certificate of Analysis) is a formal document that attests to Firsocostat's compliance with Firsocostat specifications and serves as a tool for batch-level quality control.
Firsocostat CoA mostly includes findings from lab analyses of a specific batch. For each Firsocostat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Firsocostat may be tested according to a variety of international standards, such as European Pharmacopoeia (Firsocostat EP), Firsocostat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Firsocostat USP).
LOOKING FOR A SUPPLIER?
